SLC5A2 and heart failure: This was the first large randomized clinical trial that showed empagliflozin (EMPA), a specific SGLT-2 inhibitor, was not only effective in reducing MACE but that the outcome was driven primarily by a reduction in cardiovascular deaths and hospitalization for heart failure [5,6,7].